RPI-1
RPI-1 is an ATP-dependent RET kinase inhibitor. Oral treatment with RPI-1 caused growth arrest or regression in 81% treated tumors. Following treatment suspension, tumor inhibition was maintained (51%, P<0.05, 100 days) and cures were achieved in 2/11 mice. In vivo effects of RPI-1 were reflected in activation of BAD, cleavage of caspases, apoptotic DNA fragmentation and inhibition of VEGF production observed in in vitro RPI-1-treated TT cells..
Product Specifications
CAS Number
269730-03-2
Product Name Alternative
RPI-1 | RPI1 | RPI 1
Field of Research
Neuroscience
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 125 mg/mL (420.44 mM)
Smiles
COc1c (cc2c (c1) /C (=C/c1ccc (cc1) O) /C (=O) N2) OC
Molecular Formula
C17H15NO4
Molecular Weight
297.31
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
1,3-dihydro-3-[ (4-hydroxyphenyl) methylene]-5,6-dimethoxy-2H-indol-2-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Anti Presynaptic Membrane Receptor Antibody ELISA kit
Canine C type lectin domain family 1 member A (CLEC1A) ELISA kit
TRNAA19 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
Recombinant Narcissus mosaic virus Movement protein TGB2 (ORF3)